Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritonavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 known ✓ | P08684 | 20/20 | 1.00 |
| ▸ | CYP3A5 known ✓ | P20815 | 1/20 | 1.00 |
| ▸ | CYP3A7 known ✓ | P24462 | 1/20 | 1.00 |
| ▸ | CYP3A43 known ✓ | Q9HB55 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritonavir SCHEMBL7531251 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL825767 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL17787453 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL24777041 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL7806137 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL23927481 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL12175481 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL20257193 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL3178401 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 | |
| Ritonavir SCHEMBL20322359 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C19CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 61823 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-224270292-U | Palladium carbon filter pressing device in ritonavir intermediate BDH production process | Xiamen Sichong Biopharmaceutical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-116832004-B | Nemactevir and ritonavir compound tablet and preparation method thereof | Anhui Biochem Bio-Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-5559158-A | PROTEASE INHIBITOR ADSORBED ON SILICA, MICROCRYSTALLINE CELLULOSE, IMPROVED BIOAVAILABILITY,TREATMENT OF HIV | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | claimed |
| WO-1996026734-A1 | ANTIVIRAL COMBINATIONS OF BCH-189 AND RITONAVIR | GLAXO GROUP LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | claimed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | claimed |
| EP-0721330-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1996-07-17 | — | — | EP | claimed |
| EP-0719142-A1 | PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1996-07-03 | — | — | EP | claimed |
| US-5484801-A | Pharmaceutical composition for inhibiting HIV protease | ABBOTT LABORATORIES (US) | 1996-01-16 | — | — | US | claimed |
| WO-1995020384-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-08-03 | — | — | WO | claimed |
| WO-1995009614-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1995-04-13 | — | — | WO | claimed |
| WO-1995007696-A1 | PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-23 | — | — | WO | claimed |